Eylea Hd: Uses, Side Effects and Dosage

What Eylea HD is used for:

Eylea (“I-LEE-ah”) HD is a solution which is injected into the eye (intravitreal injection) by your healthcare professional with local anesthesia (freezing) to treat the eye conditions called:

• neovascular (wet) age-related macular degeneration – (wet) AMD,
• diabetic macular edema (DME),
• macular edema caused by retinal vein occlusion (RVO).

How Eylea HD works:

Growth factors (known as VEGF-A and PlGF) can cause extra blood vessels to grow and leak in the back of the eye, which can cause loss of vision.

Vascular Endothelial Growth Factor (VEGF) and Placental Growth Factor (PlGF) are proteins that play an important role in making the abnormal blood vessels that contribute to the progression of wet AMD and the macular edema (swelling) that is seen with diabetic macular edema (DME) and retinal vein occlusion (RVO). These blood vessels are fragile and can leak fluid and blood into the macula, leading to vision loss. DME is a swelling of the retina occurring in patients with diabetes due to leaking of fluid from blood vessels within the macula. In patients with RVO, one or more blood vessels which transport blood away from the retina are blocked. This results in swelling of the macula. The macula is the portion of retina responsible for fine vision. When the macula swells with fluid, central vision becomes blurry.

Aflibercept, the active substance in Eylea HD, blocks these growth factors, and has been shown to help improve vision or slow vision loss from wet AMD, DME, and RVO.

The ingredients in Eylea HD are:

Medicinal ingredient(s): aflibercept

Non-medicinal ingredients: sucrose, L-arginine monohydrochloride, L-histidine monohydrochloride monohydrate, L-histidine, polysorbate 20, water for injection.

Eylea HD comes in the following dosage forms:

Eylea HD is a sterile, clear to slightly opalescent, colourless to pale yellow, solution for injection which is iso-osmotic (similar properties to the inside of your eye). Solution for intravitreal injection 8 mg / 0.07 mL in vial or pre-filled syringe with integrated OcuClick dosing system.

Vials:

Each carton includes a single-dose glass vial containing a fill volume of 0.263 mL for Eylea HD solution for injection with a rubber stopper, and an 18 gauge filter needle.

Pre-filled Syringes:

Each carton includes a single-dose pre-filled syringe with OcuClick dosing system containing a fill volume of 0.184 mL for Eylea HD solution for injection.

Do not use Eylea HD if:

• you are allergic (hypersensitive) to aflibercept or any of the other ingredients of Eylea HD listed below or component of the container
• you have inflammation of the eye (symptoms include eye pain, redness and trouble seeing)
• you have an infection in or around the eye (ocular or periocular infection)

• you are or plan to become pregnant: There is no experience of using Eylea HD in pregnant women. In animals, high doses have been shown to have toxic effects on the fetus. Therefore, Eylea HD is not recommended during pregnancy. If you are pregnant or planning to become pregnant, discuss this with your healthcare professional before treatment with Eylea HD. Women of childbearing potential have to use effective contraception during treatment and for at least 4 months after the last intravitreal injection of Eylea HD.

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take Eylea HD. Talk about any health conditions or problems you may have, including if you:

• have glaucoma (increased eye pressure)
• have a history of seeing flashes of light or floaters, or if you have a sudden increase in the size or number of floaters.
• have previously had a stroke or experienced temporary signs of stroke (weakness or paralysis of limbs or face, difficulty speaking or understanding).
• have had eye surgery in the last four weeks or if eye surgery is planned in the next four weeks

Other warnings you should know about:

• The safety and efficacy of Eylea HD when administered to both eyes at the same time has not been studied and may increase risk of experiencing side effects.
• Injection with Eylea HD may trigger an increase in eye pressure (intraocular pressure) within 60 minutes of the injection. Your healthcare professional may monitor eye pressure after each injection.
• Although uncommon, all intravitreal injections, including those with Eylea HD, carry a risk of serious infection or inflammation inside the eye (endophthalmitis), a risk of infection or inflammation of the white part of the eye (scleritis), inflammation of the vessels of the retina (retinal vasculitis with or without occlusion), detachment or tear of the retina at the back of the eye (symptoms include eye pain, worsening eye redness, blurred or decreased vision, sensitivity to light, sudden loss of vision, flashing lights and black spots), cataracts (clouding of the lens in the front of the eye), and bleeding inside the eye (vitreous hemorrhage and hyphema). Tell your healthcare professional immediately if you develop any of these symptoms.
• Tell your healthcare professional immediately if you develop signs or symptoms of a possible allergic reaction (for example, fast pulse, low blood pressure, sweating, allergic skin reactions such as rash, itching or stinging).

Before you use Eylea HD, talk to your healthcare professional if:

• You are breastfeeding: Eylea HD is not recommended during breastfeeding as it is not known whether aflibercept passes into human milk. A risk to the breastfed child cannot be excluded. Ask your healthcare professional for advice before starting Eylea HD treatment. A decision must be made whether to discontinue breastfeeding or to abstain from Eylea HD therapy.

The use of Eylea HD in children and adolescents has not been studied and is therefore not recommended.

Driving and Using Machines

After your Eylea HD injection, you may experience some temporary visual disturbances. Give yourself time after taking Eylea HD to see how you feel before driving a vehicle or operating machinery. Do not drive or use machinery if you are experiencing visual disturbances.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

How to take Eylea HD:

Usual dose:

Eylea HD is intended for injection into the eye. It must only be administered by a healthcare professional experienced in giving eye injections.

Eylea HD will be injected under aseptic (clean and sterile) conditions. Before the injection, your healthcare professional will use a disinfectant eyewash to clean your eye carefully to prevent infection. Your healthcare professional will also give you a local anesthetic to reduce or prevent any pain you might have with the injection.

Treatment of wet AMD

Eylea HD 8 mg (0.07 mL) will be administered once a month (every 4 weeks) for the first 3 months (12 weeks) then you may receive an injection every 2 months (8 weeks) or every 3 months (12 weeks) or every 4 months (16 weeks) thereafter. After 12 months (52 weeks), your healthcare professional will decide whether the dosing interval may need to be adjusted to a maximum of every 6 months (24 weeks) using increments of up to 4 weeks.

Treatment of DME

Eylea HD 8 mg (0.07 mL) will be administered once a month (every 4 weeks) for the first 3 months (12 weeks) then you may receive an injection every 2 months (8 weeks) or every 3 months (12 weeks) or every 4 months (16 weeks) thereafter. After 12 months (52 weeks), your healthcare professional will decide whether the dosing interval may need to be adjusted to a maximum of every 6 months (24 weeks) using increments of up to 4 weeks.

Treatment of RVO

Eylea HD 8 mg (0.07 mL) will be administered once a month (every 4 weeks) for the first 3 months (12 weeks), then once every 2 months (8 weeks). Your healthcare professional will decide whether the dosing interval may need to be adjusted based on your condition to a maximum of every 4 months (16 weeks) using increments of 4 weeks. The interval between two doses should not be shorter than one month (4 weeks). Your vision will be monitored by your healthcare professional regularly to determine the need for continued treatment.

Use in children: The safety and efficacy of Eylea HD have not been studied in patients who are younger than 18 years of age. Health Canada has not authorized Eylea HD for pediatric use.

Before stopping Eylea HD treatment:

Consult your healthcare professional before stopping the treatment. If you have any further questions about the use of this product, ask your healthcare professional.

Overdose:

Missed dose:

If a dose of Eylea HD is missed, make a new appointment for an examination and injection as soon as possible.

Possible side effects from using Eylea HD:

These are not all the possible side effects you may have when taking Eylea HD. If you experience any side effects not listed here, tell your healthcare professional.

Like all medicines, Eylea HD can cause side effects, although not everybody gets them.

With administration of Eylea HD, there may be some side effects due to the injection procedure. Some of these may be serious and include increase of pressure inside the eye (intraocular pressure) in AMD, DME and RVO clinical studies for Eylea HD. These serious side effects related to the injection procedure occurred in 1 in 242 patients treated with Eylea HD in the AMD study; 1 in 491 patients treated with Eylea HD in the DME study; and 1 in 295 patients treated with Eylea HD in the RVO study.

The following is a list of the side effects reported to be possibly related to the Eylea HD injection procedure or to the medicine. Please do not get alarmed, you might not experience any of these. Always discuss any suspected side effects with your healthcare professional.

Common side effects (between 1 and 10 in every 100 patients may be affected):

• moving spots in vision (vitreous floaters)
• bloodshot eye caused by bleeding from small blood vessels in the outer layers of the eye (conjunctival hemorrhage)
• detachment of the vitreous (gel-like substance inside the eye) from the retina (vitreous detachment)
• eye pain
• damage to the front layer of the eyeball (corneal abrasion, punctate keratitis)
• generalized allergic reactions (hypersensitivity)*

* Allergic reactions like rash, itching (pruritus) and hives (urticaria) were reported.

Uncommon side effects (between 1 and 10 in every 1,000 patients may be affected):

• certain forms of clouding of the lens (subcapsular, corticol, or nuclear cataract)
• blurred vision
• decreased sharpness of vision (retinal pigment epithelium tear, detachment of the retinal pigment epithelium)
• damage to the front layer of the eyeball (corneal erosion)
• pain or bleeding at the injection site (injection site pain or hemorrhage)
• a feeling of having something in the eye (foreign body sensation in eyes)
• redness of the eye (conjunctival hyperemia, ocular hyperemia)
• increased tear production (lacrimation increased)
• swelling of the eyelid (eyelid edema)
• inflammation of certain parts of the eye (iridocyclitis, vitritis, uveitis)
• inflammation in the iris of the eye (iritis)
• certain forms of clouding of the lens (lenticular opacities)
• swelling of the front of the eyeball (corneal edema)

Frequency not known (frequency cannot be estimated from the available data):

• inflammation of the white part of the eye associated with redness and pain (episcleritis)
• blindness

The following side effects can also be expected with Eylea HD:

• inflammation of certain parts of the eye (anterior chamber flare)
• damage of the front layer of the eyeball (corneal epithelium defect)
• pus in front of the iris (coloured part of the eye) (hypopyon)
• clouding of the lens due to injury (traumatic cataract)
• severe allergies (severe anaphylactic/anaphylactoid reactions)

The use of VEGF inhibitors similar to those contained in Eylea HD, but which have an effect throughout the body (systemic effect) is potentially related to risk of arterial thromboembolic events (ATEs) (of blood clots blocking blood vessels) which may lead to heart attack or stroke. There is a theoretical risk of such events following injection of Eylea HD into the eye.

As with all therapeutic proteins, Eylea HD may cause an immune reaction (formation of antibodies).

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your healthcare professional.

Serious side effects and what to do about them

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

Reporting side effects

Storage:

• Keep out of reach and sight of children.
• Store in a refrigerator at 2°C to 8°C. Do not freeze.

Pre-filled Syringes:

• Prior to usage, the unopened blister pack may be stored at room temperature (25°C) for up to 24 hours.
• Keep the pre-filled syringe with OcuClick dosing system in its blister pack and in the outer carton in order to protect from light.

Vials:

• Prior to usage, the unopened vial may be stored at room temperature (25°C) for up to 24 hours.
• Keep the vial in its outer carton in order to protect from light.

If you want more information about Eylea HD:

• Talk to your healthcare professional

• Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada Drug Product Database website: (https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html); the manufacturer’s website http://www.bayer.ca or by calling Bayer Medical Information at 1800-265-7382.

  Bayer Inc. 2920 Matheson Boulevard East Mississauga, Ontario L4W 5R6

  Canada

Date of Authorization 2026-10-26

© 2026, Bayer Inc.

® TM see www.bayer.ca/tm-mc